Johnny Keller

Johnny Keller

Auto-generated profile, based on publicly available information

Johnny Keller

Department of Orthopaedic Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Sarcoma
Verified
Journal Article
Open access
PDF file
KMKatja Maretty-Nielsen
Katja Maretty-Nielsen
SBSteen Baerentzen
Steen Baerentzen
JKJohnny Keller
Johnny Keller
HDHeidi Buvarp Dyrop
Heidi Buvarp Dyrop
ASAkmal Safwat
Akmal Safwat
Aim. The aim of this study was to assess the incidence of low-grade fibromyxoid sarcoma (LGFMS), present treatment results of metastatic LGFMS, and investigate the clinical significance of theFUSgene rearrangement.Methods. This study included 14 consecutive LGFMS patients treated at the Aarhus Sarcoma Centre in 1979–2010. Fluorescent in situ hybridization (FISH) analysis forFUSbreak-apart was performed for all patients.Results. The incidence of LGFMS was 0.18 per million, representing 0.6% of all soft tissue sarcomas. Four patients needed multiple biopsies/resections before the correct diagnosis was made. Four patients experienced local recurrence, and three patients developed metastases. The treatment of metastatic LGFMS varied from multiagent chemotherapy to repeated, selective surgery of operable metastases. The best response to chemotherapy was short-term stabilization of disease progression, seen with Trabectedin. The prevalence of theFUSbreak-apart was 21.4%. We found no significant difference in clinical characteristics and outcomes in correlation with theFUSbreak-apart.Conclusion. LGFMS is a rare disease with multiple challenges. TheFUSbreak-apart was not associated with local recurrence or metastases in our study. To date the only treatment resulting in disease-free periods is surgery; however further investigation into the management of metastatic LGFMS is necessary.

20 June 2013 in Sarcoma
Verified
Journal Article
Open access
PDF file
HFHanna M. Fuglø
Hanna M. Fuglø
KMKatja Maretty-Nielsen
Katja Maretty-Nielsen
DHDorrit Hovgaard
Dorrit Hovgaard
JKJohnny Ø. Keller
Johnny Ø. Keller
ASAkmal A. Safwat
Akmal A. Safwat
Michael Mørk PetersenMichael Mørk Petersen
Michael Mørk Petersen
Purpose. To assess the metastatic pattern of the histological subtype myxoid liposarcoma (MLS) with no or few round cells.Methods. Forty-five patients (F/M = 27/18, mean age 49 (range 17–85) years) were diagnosed with MLS at two Danish sarcoma centres in the period 1995–2004. A retrospective review of patients' files combined with an extraction of survival data from the Danish Centralised Civil Register was performed.Results. Seven patients had distant metastases during the observation period. Two patients had metastases at the time of diagnosis, while metastases occurred within 2.5 years in four patients, and in one patient 11.9 years after primary diagnosis. All metastases occurred at extrapulmonary sites. The first local relapse occurred within 3 years after surgery in six patients, in one patient after 4.0 years, and in one patient 7.7 years after surgery. The 5- and 10-year overall survival was 80% and 69%, respectively. Both the 5- and 10-year distant metastases-free survival was, respectively, 86%. The 5- and 10-year local relapse-free survival was, respectively, 83% and 80%.Conclusions. Patients with MLS had only extra-pulmonary metastases, and no lung metastases were found. Most local relapses and distant metastases occurred within the first 2-3 years after surgery.

26 December 2016 in Sarcoma
Verified
Journal Article
Open access
PDF file
HDHeidi Buvarp Dyrop
Heidi Buvarp Dyrop
PVPeter Vedsted
Peter Vedsted
MRMathias Rædkjær
Mathias Rædkjær
ASAkmal Safwat
Akmal Safwat
JKJohnny Keller
Johnny Keller
Background and Objectives. Sarcoma patients often experience delay before diagnosis. We examined the association between presenting symptoms/signs and time intervals for suspected sarcoma patients.Methods. 545 consecutive patients suspected for sarcoma referred over a one-year period were included. Median time intervals in routes to diagnosis were collected from medical records and questionnaires.Results. 102 patients (18.7%) had a sarcoma; 68 (12.5%) had other malignancies. Median interval for the patient (time from first symptom to first doctor visit), primary care, local hospital, sarcoma center, diagnostic, and total interval for sarcoma patients were 77, 17, 29, 17, 65, and 176 days, respectively. Sarcoma patients visited more hospital departments and had longer median primary care (+10 days) and diagnostic intervals (+19 days) than patients with benign conditions. Median primary care (−19 days) and sarcoma center (−4 days) intervals were shorter for patients with a lump versus no lump. Median patient (+40 days), primary care (+12 days), diagnostic (+17 days), and total intervals (+78 days) were longer for patients presenting with pain versus no pain. GP suspicion of malignancy shortened local hospital (−20 days) and total intervals (−104 days).Conclusions. The main part of delay could be attributed to the patient and local hospitals. Length of time intervals was associated with presenting symptoms/signs and GP suspicion.

1 September 2014 in Acta Orthopaedica
Verified
Journal Article
Open access
HDHeidi B Dyrop
Heidi B Dyrop
PVPeter Vedsted
Peter Vedsted
ASAkmal Safwat
Akmal Safwat
KMKatja Maretty-Nielsen
Katja Maretty-Nielsen
BHBjarne H Hansen
Bjarne H Hansen
JKJohnny Keller
Johnny Keller
The Danish Cancer Patient Pathway for sarcoma defines a set of alarm symptoms as criteria for referral to a sarcoma center. This may exclude cancer patients without alarm symptoms, so we investigated the presence of alarm symptoms (defined as being indicative of a sarcoma) in patients who had been referred to the Aarhus Sarcoma Center. We reviewed the medical records of all 1,126 patients who had been referred, with suspected sarcoma, from other hospitals in the period 2007-2010 for information on symptoms, clinical findings, and diagnosis. Alarm symptoms were analyzed for predictive values in diagnosing sarcoma. 179 (69%) of 258 sarcoma patients were referred with alarm symptoms (soft-tissue tumor>5 cm or deep-seated, fast-growing soft-tissue tumor, palpable bone tumor, or deep persisting bone pain). The remaining 79 sarcomas were found accidentally. "Size over 5 cm" for soft-tissue tumors, and "deep persisting bone pain" for bone tumors had the highest sensitivity and positive predictive value. Of the 79 sarcoma patients who were referred without alarm symptoms, 7 were found accidentally on imaging, 5 were referred with suspected recurrence of a sarcoma, 64 were referred with a confirmed histological diagnosis, and 3 were referred for other reasons. Defined alarm symptoms are predictive of sarcoma, but one-third of the patients were found accidentally. Further studies on presenting symptoms in primary care are needed to assess the true value of alarm symptoms.

1 January 1990 in Acta Orthopaedica
Verified
Journal Article
Open access
PDF file
JKJohnny Keller
Johnny Keller
PKPer Kjærsgaard-Andersen
Per Kjærsgaard-Andersen
IBIngrid Bayer-Kristensen
Ingrid Bayer-Kristensen
FMFlemming Melsen
Flemming Melsen
The influence of indomethacin on remodeling activity in normal trabecular and cortical bone and its influence on cortical bone close to a mid-tibial drill hole, 2 mm in diameter were histomorphometrically evaluated. Eight rabbits were treated with indomethacin (12.5 mg/kg/day), and another 8 rabbits served as controls. After 3 days, the mean plasma indomethacin level was 542 ng/mL, resulting in an almost complete inhibition of prostaglandin synthesis as reflected by the serum levels. In the control rabbits the remodeling activity after 6 weeks was increased 1 mm away from the drill hole but not at 3 and 8 mm. In conclusion, indomethacin had no effect on the activated remodeling process in cortical bone neighboring a small drill hole or on remodeling in nontraumatized cortical and cancellous bone. This suggests that the inhibitory effect of indomethacin on the remodeling process following local trauma to bone depends on the extent of the trauma.

1 October 1996 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
JRJennifer Rodenberg
Jennifer Rodenberg
OJOlaf Myhre Jensen
Olaf Myhre Jensen
JKJohnny Keller
Johnny Keller
ONOle S. Nielsen
Ole S. Nielsen
CBCody Bünger
Cody Bünger
AJAnne Grethe Jurik
Anne Grethe Jurik